As of late 2015, major health care issues include the rising awareness of behavioral health care, a growing will to reduce total health care costs, and the rise of biosimilar drugs, according to PwC. Historically, large health care companies were unable to provide full, specific costs of services they provided.
Related to generic drugs, biosimilar drugs are substitute medicines almost identical to brand-name drugs, notes PwC. In the United States, the first biosimilar drug to achieve FDA approval was Zarxio, a medication for cancer patients that entered the market at a very affordable price.
Biosimilars are derived from living organisms, which strongly differentiates these medicines from previous alternatives, states PwC. Biosimilars share this quality with biologics, the type of expensive medication that biosimilars were developed to replace. Behavioral health care is important for properly managing mental illness in the workplace. As awareness of behavioral health care rises, many parties are working to reduce the stigma associated with mental illness.